TCI Wealth Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

TCI Wealth Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-192	Closed	-$3.08K	–	658
2023 Q1	$3.08K	Buy	192 +74	+63%	+$1.37K	﹤0.01%	1841
2022 Q4	$2.16K	Hold	118	–	–	﹤0.01%	1957
2022 Q3	$2K	Hold	118	–	–	﹤0.01%	1913
2022 Q2	$2K	Hold	118	–	–	﹤0.01%	1977
2022 Q1	$3K	Hold	118	–	–	﹤0.01%	1863
2021 Q4	$3K	Hold	118	–	–	﹤0.01%	1990
2021 Q3	$2K	Hold	118	–	–	﹤0.01%	2104
2021 Q2	$2K	Buy	+118	New	+$2.07K	﹤0.01%	1976

Other funds holding CRNX

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TCI Wealth Advisors's CRNX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2023, closing a stake of 192 shares — an estimated $3.08K sold.

TCI Wealth Advisors first reported a position in CRNX in Q2 2021 and held it in 8 quarters. The position peaked at $3.08K in Q1 2023. 140 funds tracked by Wall St. Rank hold CRNX as of Q2 2023.

TCI Wealth Advisors reported no remaining Crinetics Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 192 Crinetics Pharmaceuticals shares in Q2 2023, an estimated $3.08K.
TCI Wealth Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2021 and held it in 8 quarters.
TCI Wealth Advisors's Crinetics Pharmaceuticals position peaked at $3.08K in Q1 2023.
140 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.